EA201892698A1 - Производные пиразолиламинобензимидазола в качестве ингибиторов jak - Google Patents

Производные пиразолиламинобензимидазола в качестве ингибиторов jak

Info

Publication number
EA201892698A1
EA201892698A1 EA201892698A EA201892698A EA201892698A1 EA 201892698 A1 EA201892698 A1 EA 201892698A1 EA 201892698 A EA201892698 A EA 201892698A EA 201892698 A EA201892698 A EA 201892698A EA 201892698 A1 EA201892698 A1 EA 201892698A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrazolylaminobenzimidazole
derivatives
jak inhibitors
methods
compounds
Prior art date
Application number
EA201892698A
Other languages
English (en)
Other versions
EA038129B1 (ru
Inventor
Джоли Энн Бастиан
Джошуа Райан Клейтон
Дэвид Эндрю Коатес
Дэниел Джон Солл
Тимоти Эндрю Вудс
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201892698A1 publication Critical patent/EA201892698A1/ru
Publication of EA038129B1 publication Critical patent/EA038129B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В данном изобретении предложены соединения формулыгде R, и R1-R3 являются такиим, как описано в данном документе, способы лечения пациентов от определенных типов аутоиммунных заболеваний и рака и способы получения предложенных соединений.
EA201892698A 2016-07-14 2017-07-10 Производные пиразолиламинобензимидазола в качестве ингибиторов jak EA038129B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362208P 2016-07-14 2016-07-14
PCT/US2017/041388 WO2018013486A1 (en) 2016-07-14 2017-07-10 Pyrazolylaminobenzimidazole derivatives as jak inhibitors

Publications (2)

Publication Number Publication Date
EA201892698A1 true EA201892698A1 (ru) 2019-06-28
EA038129B1 EA038129B1 (ru) 2021-07-09

Family

ID=59366549

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892698A EA038129B1 (ru) 2016-07-14 2017-07-10 Производные пиразолиламинобензимидазола в качестве ингибиторов jak

Country Status (22)

Country Link
US (2) US10323019B2 (ru)
EP (1) EP3484875B1 (ru)
JP (1) JP6712331B2 (ru)
KR (1) KR102225840B1 (ru)
CN (1) CN109476643B (ru)
AU (1) AU2017296026B2 (ru)
BR (1) BR112018075086B1 (ru)
CA (1) CA3030697C (ru)
CY (1) CY1124308T1 (ru)
DK (1) DK3484875T3 (ru)
EA (1) EA038129B1 (ru)
ES (1) ES2877198T3 (ru)
HR (1) HRP20210965T1 (ru)
HU (1) HUE054912T2 (ru)
LT (1) LT3484875T (ru)
MX (1) MX2019000542A (ru)
NZ (1) NZ748942A (ru)
PL (1) PL3484875T3 (ru)
PT (1) PT3484875T (ru)
RS (1) RS61991B1 (ru)
SI (1) SI3484875T1 (ru)
WO (1) WO2018013486A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230141115A (ko) 2022-03-31 2023-10-10 한림대학교 산학협력단 신규한 2-아릴-1H-벤조[d]이미다졸 유도체, 이의 제조 방법 및 이의 항암제로서의 용도
KR102582097B1 (ko) 2022-12-28 2023-09-25 (주)메디언스 야누스키나아제 표적 억제제 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204246A1 (en) * 2007-04-18 2010-08-12 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer
US8445676B2 (en) * 2008-10-08 2013-05-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2010068806A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
EP2523957A1 (en) * 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
PE20140146A1 (es) * 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US8962608B2 (en) * 2011-09-22 2015-02-24 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3715346B1 (en) * 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1

Also Published As

Publication number Publication date
EA038129B1 (ru) 2021-07-09
EP3484875B1 (en) 2021-04-07
CA3030697C (en) 2021-02-23
BR112018075086A2 (pt) 2019-03-12
CY1124308T1 (el) 2022-07-22
SI3484875T1 (sl) 2021-08-31
ES2877198T3 (es) 2021-11-16
CA3030697A1 (en) 2018-01-18
LT3484875T (lt) 2021-07-26
WO2018013486A1 (en) 2018-01-18
PL3484875T3 (pl) 2021-11-02
JP2019525908A (ja) 2019-09-12
US10344018B2 (en) 2019-07-09
HRP20210965T1 (hr) 2021-09-17
US20180325873A1 (en) 2018-11-15
US20190177300A1 (en) 2019-06-13
DK3484875T3 (da) 2021-06-28
US10323019B2 (en) 2019-06-18
EP3484875A1 (en) 2019-05-22
NZ748942A (en) 2020-08-28
CN109476643A (zh) 2019-03-15
AU2017296026B2 (en) 2019-11-21
HUE054912T2 (hu) 2021-10-28
BR112018075086B1 (pt) 2024-02-27
MX2019000542A (es) 2019-07-04
RS61991B1 (sr) 2021-07-30
KR102225840B1 (ko) 2021-03-11
AU2017296026A1 (en) 2018-12-20
KR20190015561A (ko) 2019-02-13
JP6712331B2 (ja) 2020-06-17
PT3484875T (pt) 2021-07-05
CN109476643B (zh) 2021-06-08

Similar Documents

Publication Publication Date Title
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1124046T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
EA202191730A1 (ru) Ингибиторы kif18a
EA201991198A1 (ru) АМИНОТИАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX2019013031A (es) Análogos de rapamicina como inhibidores de mtor.
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CY1123988T1 (el) Ενωση πυριδινης
EA201892740A2 (ru) Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
EA201991197A1 (ru) БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201691940A1 (ru) Новые соединения
CY1125047T1 (el) Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης
SA518391864B1 (ar) مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
EA201990400A1 (ru) Соединения и композиции и их применение
EA201792287A1 (ru) Способы лечения рака
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM